Update information
September 2024: Recommendation 1.1 has been amended to match the updated marketing authorisation for burosumab, which has also been updated in section 3.1.
ISBN: 978-1-4731-3131-6
September 2024: Recommendation 1.1 has been amended to match the updated marketing authorisation for burosumab, which has also been updated in section 3.1.
ISBN: 978-1-4731-3131-6